{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:56:56Z","timestamp":1790233016417,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,10,1]]},"DOI":"10.1093\/ije\/31.5.951","type":"journal-article","created":{"date-parts":[[2002,11,15]],"date-time":"2002-11-15T23:03:15Z","timestamp":1037401395000},"page":"951-958","source":"Crossref","is-referenced-by-count":51,"title":["Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks"],"prefix":"10.1093","volume":"31","author":[{"name":"Cascade Collaboration","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2002,10]]},"reference":[{"key":"key\n\t\t\t\t20180328145649_R1","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz A, Xu J. Models for the incubation of AIDS and variations according to age and period. Stat Med1996;15:2459\u201373.","DOI":"10.1002\/(SICI)1097-0258(19961130)15:22<2459::AID-SIM464>3.0.CO;2-Q"},{"key":"key\n\t\t\t\t20180328145649_R2","doi-asserted-by":"crossref","unstructured":"Collaborative Group on AIDS Incubation and HIV Survival. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet2000;355:1131\u201337.","DOI":"10.1016\/S0140-6736(00)02061-4"},{"key":"key\n\t\t\t\t20180328145649_R3","doi-asserted-by":"crossref","unstructured":"Tarwater PM, Mellors J, Gore ME. Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. Am J Epidemiol2001;154:675\u201381.","DOI":"10.1093\/aje\/154.7.675"},{"key":"key\n\t\t\t\t20180328145649_R4","doi-asserted-by":"crossref","unstructured":"Egger M, Hirschel B, Francioli P et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ1997;315:1194\u201399.","DOI":"10.1136\/bmj.315.7117.1194"},{"key":"key\n\t\t\t\t20180328145649_R5","doi-asserted-by":"crossref","unstructured":"Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet1998;352:1725\u201330.","DOI":"10.1016\/S0140-6736(98)03201-2"},{"key":"key\n\t\t\t\t20180328145649_R6","doi-asserted-by":"crossref","unstructured":"Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med1998;338:853\u201360.","DOI":"10.1056\/NEJM199803263381301"},{"key":"key\n\t\t\t\t20180328145649_R7","doi-asserted-by":"crossref","unstructured":"Detels R, Mu\u00f1oz A, McFarlane G et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicentre AIDS Cohort Study Investigators. JAMA1998;17:1497\u2013503.","DOI":"10.1001\/jama.280.17.1497"},{"key":"key\n\t\t\t\t20180328145649_R8","doi-asserted-by":"crossref","unstructured":"Dorrucci M, Balducci M, Pezzotti P et al. Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: estimates of the population effect of treatment. J AIDS1999;22:65\u201370.","DOI":"10.1097\/00042560-199909010-00008"},{"key":"key\n\t\t\t\t20180328145649_R9","doi-asserted-by":"crossref","unstructured":"CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet2000; 355:1158\u201359.","DOI":"10.1016\/S0140-6736(00)02069-9"},{"key":"key\n\t\t\t\t20180328145649_R10","doi-asserted-by":"crossref","unstructured":"Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS1999;13:1933\u201342.","DOI":"10.1097\/00002030-199910010-00017"},{"key":"key\n\t\t\t\t20180328145649_R11","doi-asserted-by":"crossref","unstructured":"Mocroft A, Katlama C, Johnson AM et al. AIDS across Europe, 1994\u201398: the EuroSIDA study. Lancet2000;356:291\u201396.","DOI":"10.1016\/S0140-6736(00)02504-6"},{"key":"key\n\t\t\t\t20180328145649_R12","doi-asserted-by":"crossref","unstructured":"Ledergerber B, Telenti A, Egger M for the Swiss HIV Cohort Study. Risk of HIV related Kaposi\u2019s sarcoma and non-Hodgkin\u2019s lymphoma with potent antiretroviral therapy: prospective cohort study. BMJ1999;319:23\u201324.","DOI":"10.1136\/bmj.319.7201.23"},{"key":"key\n\t\t\t\t20180328145649_R13","doi-asserted-by":"crossref","unstructured":"Forrest DM, Seminari E, Hogg RS et al. The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. Clin Infect Dis1998;27:1379\u201385.","DOI":"10.1086\/515030"},{"key":"key\n\t\t\t\t20180328145649_R14","doi-asserted-by":"crossref","unstructured":"Detels R, Tarwater P, Phair JP et al. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic therapies before and after AIDS diagnosis. AIDS2001;15:347\u201355.","DOI":"10.1097\/00002030-200102160-00008"},{"key":"key\n\t\t\t\t20180328145649_R15","doi-asserted-by":"crossref","unstructured":"CASCADE Collaboration. Changes in uptake of antiretroviral therapy and survival in persons with known duration of HIV infection in Europe. HIV Medicine2000;1:224\u201331.","DOI":"10.1046\/j.1468-1293.2000.00033.x"},{"key":"key\n\t\t\t\t20180328145649_R16","doi-asserted-by":"crossref","unstructured":"Anon. Expanded European AIDS case definition. Lancet1993; 341:441.","DOI":"10.1016\/0140-6736(93)93040-8"},{"key":"key\n\t\t\t\t20180328145649_R17","doi-asserted-by":"crossref","unstructured":"Cox DR. Regression models and life tables. J R Statist Soc1972:34:187\u2013220.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"key\n\t\t\t\t20180328145649_R18","unstructured":"Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley and Sons, 1990."},{"key":"key\n\t\t\t\t20180328145649_R19","doi-asserted-by":"crossref","unstructured":"Andersen PK, Borgan O, Gill RD, Keiding N. Statistical Models based on Counting Processes. New York: Springer Verlag, 1993.","DOI":"10.1007\/978-1-4612-4348-9"},{"key":"key\n\t\t\t\t20180328145649_R20","doi-asserted-by":"crossref","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Statist Assoc1999;94:496\u2013509.","DOI":"10.1080\/01621459.1999.10474144"},{"key":"key\n\t\t\t\t20180328145649_R21","doi-asserted-by":"crossref","unstructured":"Cox DR. Partial likelihood. Biometrika1975;62:269\u201376.","DOI":"10.1093\/biomet\/62.2.269"},{"key":"key\n\t\t\t\t20180328145649_R22","doi-asserted-by":"crossref","unstructured":"CASCADE Collaboration. The relationships between the HIV test interval, demographic factors and HIV disease progression. Epidemiol Infect2001;127:91\u2013100.","DOI":"10.1017\/S0950268801005805"},{"key":"key\n\t\t\t\t20180328145649_R23","doi-asserted-by":"crossref","unstructured":"Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modelling marginal distributions. J Am Statist Assoc1989;84:1065\u201373.","DOI":"10.1080\/01621459.1989.10478873"},{"key":"key\n\t\t\t\t20180328145649_R24","unstructured":"Huber PJ. The behaviour of maximum likelihood estimates under non-standard conditions. In: Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. Berkeley, CA: University of California Press, 1967, pp. 221\u201333."},{"key":"key\n\t\t\t\t20180328145649_R25","unstructured":"Clayton C, Hills M. Statistical Models in Epidemiology. Oxford: Oxford University Press, 1993."},{"key":"key\n\t\t\t\t20180328145649_R26","unstructured":"StataCorp. Stata Statistical Software: Release 7.0. College Station, TX: Stata Corporation, 2001."},{"key":"key\n\t\t\t\t20180328145649_R27","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz A, Gange SJ, Jacobsen LP. Distinguishing efficacy, individual effectiveness and population effectiveness of therapies. AIDS2000;6:754\u201356.","DOI":"10.1097\/00002030-200004140-00020"},{"key":"key\n\t\t\t\t20180328145649_R28","unstructured":"Anon. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR1992;41(RR-4):1\u201311."},{"key":"key\n\t\t\t\t20180328145649_R29","doi-asserted-by":"crossref","unstructured":"Kirk O, Pedersen C, Cozzi Lepri A et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood2001;98:3406\u201312.","DOI":"10.1182\/blood.V98.12.3406"}],"container-title":["International Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ije\/article-pdf\/31\/5\/951\/18478949\/310951.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T09:26:03Z","timestamp":1583918763000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ije\/article\/31\/5\/951\/745799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10,1]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2002,10]]},"published-print":{"date-parts":[[2002,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ije\/31.5.951","relation":{},"ISSN":["1464-3685","0300-5771"],"issn-type":[{"value":"1464-3685","type":"electronic"},{"value":"0300-5771","type":"print"}],"subject":[],"published-other":{"date-parts":[[2002,10]]},"published":{"date-parts":[[2002,10,1]]}}}